Posting of Notice of AGM and Annual Report
Summary by AI BETAClose X
3 September 2026
("EDX Medical" or the "Company")
Posting of Notice of AGM and Annual Report
CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services for major diseases, announces that its annual general meeting ("AGM") will be held at the Henrietta Room, 1 Wimpole Street, Westminster, London, W1G 0AE on Monday, 28 September 2026 at 2:00 p.m.
The annual report and financial statements for the year ended 31 March 2026, notice of AGM and form of proxy will be posted today, 3 September 2026, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/.
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX). The Company develops and supplies class-leading clinical diagnostics products and services.
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. The Company operates its own laboratory facilities in Cambridge UK, and has strategic product and technology partnerships with leading life sciences and healthcare organisations. Products and services are available to healthcare providers and individuals, and the Company also offers an employee health screening programme to employers.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the early detection and characterisation of disease to enable personalised treatment. Early disease detection and personal treatment optimisation is considered to be the most impactful way of improving patient outcomes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago SSE
- 2 hours ago Ninety One
- 2 hours ago Moneysupermarket.com Group
- 2 hours ago BlackRock Smaller Companies Trust
- 3 hours ago Rathbones Group